{"filing":{"accession_number":"0001628280-26-061973","cik":"0001048477","ticker":"BMRN","company_name":"BIOMARIN PHARMACEUTICAL INC","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"bmrn-20260915.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm"},"events":[{"id":33504,"run_id":30806,"accession_number":"0001628280-26-061973","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"BioMarin announced discontinuation of VOXZOGO development for children with Noonan syndrome, a clinical and strategic decision affecting the company's pipeline and future revenue prospects. While not a specific operational category (workforce reduction, restructuring, or material contract), this represents a material operational/strategic event—the termination of a development program—that would affect a reasonable investor's assessment of the company's product portfolio and growth trajectory. The company explicitly states this decision was not safety or efficacy related, suggesting it was driven by feasibility and market considerations.","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36964,"accession_number":"0001628280-26-061973","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BioMarin announced discontinuation of VOXZOGO development for children with Noonan syndrome, a clinical and strategic decision affecting the company's pipeline and future revenue prospects. While not a specific operational category (workforce reduction, restructuring, or material contract), this represents a material operational/strategic event—the termination of a development program—that would affect a reasonable investor's assessment of the company's product portfolio and growth trajectory. The company explicitly states this decision was not safety or efficacy related, suggesting it was driven by feasibility and market considerations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:36:37.040446+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36964,"accession_number":"0001628280-26-061973","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BioMarin announced discontinuation of VOXZOGO development for children with Noonan syndrome, a clinical and strategic decision affecting the company's pipeline and future revenue prospects. While not a specific operational category (workforce reduction, restructuring, or material contract), this represents a material operational/strategic event—the termination of a development program—that would affect a reasonable investor's assessment of the company's product portfolio and growth trajectory. The company explicitly states this decision was not safety or efficacy related, suggesting it was driven by feasibility and market considerations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:36:37.040446+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-09-15"}]}